GEN Exclusives

More »

GEN News Highlights

More »
Jan 30, 2012

BTG’s Varicose Veins Therapy Meets All Endpoints in First U.S. Pivotal Trial

  • BTG reported positive data from the first of two pivotal Phase III studies evaluating Varisolve® (polidocanol endovenous microfoam (PEM)) in patients with symptomatic and visible varicose veins and saphenofemoral junction incompetence. The firm said it remains on track to file for regulatory approval of the treatment in the U.S. by the end of 2012, if additional ongoing trials are successful.

    The placebo-controlled 1,500-patient Vanish-2 study met all its primary, secondary and tertiary efficacy endpoints. The primary endpoint was measured by the VVSymQ™ score, a patient-reported outcome measure of varicose vein symptoms, which was developed by BTG in accordance with FDA guidelines. The Phase III Vanish-1 study, and a separate study (VV017) evaluating Varisolve after heat ablation, are both due to report during the first half of 2012.

    A European Phase III clinical trial showed that 90% of patients treated with PEM had no reflux in the great saphenous veins (GSV) after three months and fewer than 10% of patients had recurrence at one year.

    The PEM drug/device combination generates a Co2/O2 polidocanol endovenous microfoam, and is injected into the incompetent vein under ultrasound guidance. On administration the treatment displaces blood and then the polidocanol ablates the inner lining of the vein wall, causing the vein to close. BTG says if Varisolve is approved it will be the first nonsurgical, comprehensive treatment for varicose veins above and below the knee. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?